Serum creatinine and cystatin C-based diagnostic indices for sarcopenia in advanced non-small cell lung cancer
- PMID: 35297568
- PMCID: PMC9178169
- DOI: 10.1002/jcsm.12977
Serum creatinine and cystatin C-based diagnostic indices for sarcopenia in advanced non-small cell lung cancer
Abstract
Background: Sarcopenia is an important prognostic factor of lung cancer. The serum creatinine/cystatin C ratio (CCR) and the sarcopenia index (SI, serum creatinine × cystatin C-based glomerular filtration rate) are novel screening tools for sarcopenia; however, the diagnostic accuracy of the CCR and SI for detecting sarcopenia remains unknown. We aimed to explore and validate the diagnostic values of the CCR and SI for determining sarcopenia in non-small cell lung cancer (NSCLC) and to explore their prognostic values for overall survival.
Methods: We conducted a prospective cohort study of adult patients with stage IIIB or IV NSCLC. Levels of serum creatinine and cystatin C were measured to calculate the CCR and SI. Sarcopenia was defined separately using CCR, SI, and the Asian Working Group for Sarcopenia (AWGS) 2019 criteria. Participants were randomly sampled into derivation and validation sets (6:4 ratio). The cutoff values for diagnosing sarcopenia were determined based on the derivation set. Diagnostic accuracy was analysed in the validation set through receiver operating characteristic (ROC) curves. Cox regression models and survival curves were applied to evaluate the impact of different sarcopenia definitions on survival.
Results: We included 579 participants (women, 35.4%; mean age, 58.4 ± 8.9 years); AWGS-defined sarcopenia was found in 19.5% of men and 10.7% of women. Both CCR and SI positively correlated with computed tomography-derived and bioimpedance-derived muscle mass and handgrip strength. The optimal cutoff values for CCR and SI were 0.623 and 54.335 in men and 0.600 and 51.742 in women, with areas under the ROC curves of 0.837 [95% confidence interval (CI): 0.770-0.904] and 0.833 (95% CI: 0.765-0.901) in men (P = 0.25), and 0.808 (95% CI: 0.682-0.935) and 0.796 (95% CI: 0.668-0.924) in women (P = 0.11), respectively. The CCR achieved sensitivities and specificities of 73.0% and 93.7% in men and 85.7% and 65.7% in women, respectively; the SI achieved sensitivities and specificities of 75.7% and 86.5% in men and 92.9% and 62.9% in women, respectively. CCR-defined, SI-defined, and AWGS-defined sarcopenia were independently associated with a high mortality risk [hazard ratio (HR) = 1.75, 95% CI: 1.25-2.44; HR = 1.55, 95% CI: 1.11-2.17; and HR = 1.76, 95% CI: 1.22-2.53, respectively].
Conclusions: CCR and SI have satisfactory and comparable diagnostic accuracy and prognostic values for sarcopenia in patients with advanced NSCLC. Both may serve as surrogate biomarkers for evaluating sarcopenia in these patients. However, further external validations are required.
Keywords: Decision curve analysis; Lung cancer; Muscle depletion; Muscle wasting; Survival.
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Conflict of interest statement
None declared.
Figures




Similar articles
-
Diagnostic accuracy of a 'sarcopenia index' based on serum biomarkers creatinine and cystatin C in 458,702 UK Biobank participants.Clin Nutr ESPEN. 2024 Oct;63:207-213. doi: 10.1016/j.clnesp.2024.06.041. Epub 2024 Jun 28. Clin Nutr ESPEN. 2024. PMID: 38968079
-
A new index based on serum creatinine and cystatin C is useful for assessing sarcopenia in patients with advanced cancer.Nutrition. 2021 Feb;82:111032. doi: 10.1016/j.nut.2020.111032. Epub 2020 Oct 12. Nutrition. 2021. PMID: 33172686
-
Diagnostic Value of Serum Creatinine and Cystatin-C-Based Indices and Ishii Score in Cancer-Related Sarcopenia.Diagnostics (Basel). 2023 Jun 26;13(13):2179. doi: 10.3390/diagnostics13132179. Diagnostics (Basel). 2023. PMID: 37443572 Free PMC article.
-
Diagnostic test accuracy of serum creatinine and cystatin C-based index for sarcopenia: a systematic review and meta-analysis.Age Ageing. 2024 Jan 2;53(1):afad252. doi: 10.1093/ageing/afad252. Age Ageing. 2024. PMID: 38251741
-
Serum creatinine/cystatin C ratio as a muscle mass evaluating tool and prognostic indicator for hospitalized patients: A meta-analysis.Front Med (Lausanne). 2023 Jan 9;9:1058464. doi: 10.3389/fmed.2022.1058464. eCollection 2022. Front Med (Lausanne). 2023. PMID: 36698829 Free PMC article.
Cited by
-
The diagnostic performance of Cr/CysC for sarcopenia and its predictive value on clinical outcomes in hospitalized older patients: a prospective cohort study.Eur Geriatr Med. 2024 Apr;15(2):579-588. doi: 10.1007/s41999-024-00948-5. Epub 2024 Feb 23. Eur Geriatr Med. 2024. PMID: 38393457
-
Muscle mass, creatinine, cystatin C and selective glomerular hypofiltration syndromes.Clin Kidney J. 2023 Apr 13;16(8):1206-1210. doi: 10.1093/ckj/sfad086. eCollection 2023 Aug. Clin Kidney J. 2023. PMID: 37529657 Free PMC article.
-
Association of serum creatinine to cystatin C to waist circumference ratios and hypertension: evidence from China health and retirement longitudinal study.Front Endocrinol (Lausanne). 2024 May 1;15:1375232. doi: 10.3389/fendo.2024.1375232. eCollection 2024. Front Endocrinol (Lausanne). 2024. PMID: 38752178 Free PMC article.
-
Imaging Techniques to Determine Degree of Sarcopenia and Systemic Inflammation in Advanced Renal Cell Carcinoma.Curr Urol Rep. 2023 Jul;24(7):317-334. doi: 10.1007/s11934-023-01157-6. Epub 2023 Apr 10. Curr Urol Rep. 2023. PMID: 37036632 Free PMC article. Review.
-
Creatinine-to-cystatin C ratio and body composition predict response to PD-1 inhibitors-based combination treatment in metastatic gastric cancer.Front Immunol. 2024 Apr 11;15:1364728. doi: 10.3389/fimmu.2024.1364728. eCollection 2024. Front Immunol. 2024. PMID: 38665913 Free PMC article.
References
-
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68:394–424. - PubMed
-
- Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. In Reckamp K, ed. Lung Cancer. Cancer Treatment and Research, Vol. 170. Cham: Springer; 2016. p 47–75. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical